Health Care • Biotechnology: Pharmaceutical Preparations
$8.88 ▼ -0.22
(-2.42%)
MKT CAP: $455.9M • VOL: 370.1K
52W L $8 52W H $12
PRTA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $9.7M | $135.2M | $91.4M |
| YoY Revenue Growth % | -92.8% | +47.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$214.6M | -$154.6M | -$191.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$244.1M | -$122.3M | -$147.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$163.6M | -$150.1M | -$133.9M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$163.6M | -$150.1M | -$133.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $307.5M | $471.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $280.5M | $486.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PRTA.